BioCentury
ARTICLE | Emerging Company Profile

Mermaid: taking antibodies below the cell surface

Australian-German newco is delivering antibody therapies inside liver cells by encoding them as mRNA

May 2, 2022 11:50 PM UTC

Mermaid is aiming to expand the target scope of antibodies by taking them inside the cell where traditional mAbs don’t reach.

Seizing on the moment, the Australia and Germany-based newco is marrying proof of concept from COVID-19 vaccines for lipid nanoparticle-based delivery of mRNA-encoded proteins with patent expirations on Nanobodies to create a system that can express Nanobodies inside cells...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article